TH588|cas:1609960-31-7|西域试剂

TH588,98.56%

产品编号：Bellancom-12814| CAS NO：1609960-31-7| 分子式：C₁₃H₁₂Cl₂N₄| 分子量：295.17

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-12814	￥750.00	杭州北京（现货）
Bellancom-12814	￥1400.00	杭州北京（现货）
Bellancom-12814	￥2520.00	杭州北京（现货）
Bellancom-12814	￥4550.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TH588

产品介绍

TH588 是 MTH1 (NUDT1) 高效选择性抑制剂，IC₅₀ 值 5 nM。

生物活性

TH588 is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC₅₀= 5 nM).

体外研究

TH588 (2-10μM; 7-10 days) selectively and effectively kills U2OS, HeLa, MDA-MB-231, MCF-7, SW480, and SW620 cells with IC₅₀s of 1.38, 0.83, 1.03, 1.08, 1.72, 0.8 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	U2OS, HeLa, MDA-MB-231, MCF-7, SW480, SW620, VH10, HDFn cells
Concentration:	2, 4, 6, 8, 10 μM
Incubation Time:	7-10 days
Result:	Selectively and effectively killed U2OS, HeLa, MDA-MB-231, MCF-7, SW480, and SW620 cells with IC₅₀s of 1.38, 0.83, 1.03, 1.08, 1.72, 0.8 μM, but was less toxic to several primary or immortalized cells.

体内研究
(In Vivo)

TH588 (30 mg/kg; s.c.; once daily for 35 days) reduces tumour growth in SW480 xenograft cancer model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-6 weeks female SCID mice (SW480 xenograft cancer model)
Dosage:	30 mg/kg
Administration:	Subcutaneous injection; once daily for 35 days
Result:	Reduced tumour growth in SW480 xenograft cancer model.

体内研究

TH588 (30 mg/kg; s.c.; once daily for 35 days) reduces tumour growth in SW480 xenograft cancer model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-6 weeks female SCID mice (SW480 xenograft cancer model)
Dosage:	30 mg/kg
Administration:	Subcutaneous injection; once daily for 35 days
Result:	Reduced tumour growth in SW480 xenograft cancer model.

体内研究

TH588 (30 mg/kg; s.c.; once daily for 35 days) reduces tumour growth in SW480 xenograft cancer model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-6 weeks female SCID mice (SW480 xenograft cancer model)
Dosage:	30 mg/kg
Administration:	Subcutaneous injection; once daily for 35 days
Result:	Reduced tumour growth in SW480 xenograft cancer model.

性状

Solid

溶解性数据

In Vitro:

DMSO : 16 mg/mL (54.21 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3879 mL	16.9394 mL	33.8788 mL
5 mM	0.6776 mL	3.3879 mL	6.7758 mL
10 mM	0.3388 mL	1.6939 mL	3.3879 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.47 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.47 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.47 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.47 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.47 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.47 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。